SafeStitch and TransEnterix set for merger; GenMark wants $75M in amped-up offering;

@FierceMedDev: Bard's fate hangs with jury in latest vaginal mesh lawsuit. Article | Follow @FierceMedDev

@DamianFierce: Quintiles is buying Novella with its eye on emerging biotechs. News from | Follow @DamianFierce

@MarkHFierce: For LumiQuick, is it another case of regulators trying to assert control over a surging Dx industry? Item | Follow @MarkHFierce

> SafeStitch Medical and TransEnterix have signed a deal to merge their operations. Report

> GenMark Diagnostics ($GNMK) is upsizing its previously announced stock offering, now seeking about $75 million through the sale of 7.6 million shares. News

> Patients with mitral regurgitation live longer if they get immediate surgery instead of waiting until the condition advances and requires a replacement heart valve, according to a new study. Article

> PerkinElmer has launched a prenatal test for early onset preeclampsia. Release

> New Jersey's Precision Spine has signed a deal with Japan's Mizuho Ikakogyo to get its devices distributed in the country. More

> Pathogenica gained a CE mark in Europe for its new diagnostic kit for hospital-associated infections. Item

Biotech News

@FierceBiotech: FDA's former IT boss nails down industry gig. Report from | Follow @FierceBiotech

@JohnCFierce: MannKind soars after inhaled Afrezza delivers positive PhIII results. Report | Follow @JohnCFierce

@RyanMFierce: Fate Therapeutics, founded by stem cell experts, targets $69 million IPO. Article | Follow @RyanMFierce

> The hottest disease field for biotech startups and M&A might surprise you. More

> Report: Novartis puts a $10B cap on acquisition targets, but steers clear of Onyx. Article

> Industry Voices: The man who cured aging? Article

Pharma News

@FiercePharma: With Pfizer, Novartis out, Amgen faces 1 possible rival for Onyx, per Bloomberg: AstraZeneca. Article | Follow @FiercePharma

@EricPFierce: India's Aurobindo buys, boosts capacity in sterile injectables, a hot market. Story from | Follow @EricPFierce

@CarlyHFierce: Here's the release on Boehringer earnings - BI says Pradaxa, Trajenta, Spiriva driving growth. Release | Follow @CarlyHFierce

> Tivicay marks beginning of end in growth of HIV branded market, EP says. Story

> China sales rep says Novartis ordered her to bribe doctors. Report

> New Novartis chair Reinhardt embarks on strategic review. Are divestments next? More

Drug Delivery News

@MichaelGFierce: Virus-killing nanoviricides win orphan status for dengue fever. Story | Follow @MichaelGFierce

> Receptor-targeted antifolate drugs yield fewer side effects. More

> Bind files $80M IPO to support PhII nanotech cancer drug delivery. News

> 'Smart' DNA-based nanomeds self-assemble to release cancer drug. Story

> MannKind's inhaled insulin delivery tech passes PhIII trial. Article

> NanoMedical Systems snags $2.3M to develop drug-releasing implant. Item

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.